

MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895

Regd. Office: Upper Kesalton, Tallital, Nainital-263 001, Uttarakhand,

W: www.mescopharma.com E-mail: nsparameswaran@mescosteel.com, Tel: 9871862796

MPL/33/QTR-1/2018-19

14th August, 2018

To
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai-400001

Sub: Outcome of Board Meeting dated 14th August, 2018


Dear Sir,

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed the following documents duly considered and approved by the Board of Directors in their 2nd meeting of 2018-2019 held at H-1, Zamrudpur Community Centre, Kailash Colony, New Delhi-110048 on Tuesday, 14th August, 2018 commenced at 4.00 P.M and concluded at 5.15 P.M.

1. Standalone unaudited Financial Results for first quarter ended on 30th June, 2018.
2. Limited Review Report for the quarter ended on 30th June, 2018.

This is for your information and records.

Thanking you,
For Mesco Pharmaceuticals Limited


NS Parameswaran
Managing Director
DIN: 00091097



Encl.: as above

MESCO PHARMACEUTICALS LTD

CIN : L24111UR1986PLC015895

REGD.OFFICE : UPPER KESALTON, TALLITAL, NAINITAL-263 001, UTTARAKHAND

Tel. :011-41587085, E-mail : nsparameswaran@mescosteel.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018

(In Rs.)

S. No.	PARTICULARS	Quarter Ended			Year Ended
		30.06.2018	31.03.2018	30.06.2017	31.03.2018
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Income from Operations				
	(a) Net Sales/ Income from operations	-	-	-	-
	(b) Other Income	-	-	-	-
	Total Income from Operations (net)	-	-	-	-
2	Expenses				
	(a) Cost of Material Consumed	-	-	-	-
	(b) Change in Inventories of finished goods and work in progress	-	-	-	-
	(c) Employees Benefits Expenses	-	75,000.00	67,968.00	305,581.00
	(d) Depreciation and Amortisation expenses	-	-	-	-
	(e) Finance Cost	-	-	-	150.00
	(f) Other Expenses	299,200.00	54,560.00	7,000.00	567,759.00
	Total Expenses	299,200.00	129,560.00	74,968.00	873,490.00
3	Profit/(Loss) Before Exceptional items and Tax Finance Costs & Exceptional Items (1-2)	(299,200.00)	(129,560.00)	(74,968.00)	(873,490.00)
	Exceptional Items	-	-	-	-
4	Profit/(Loss) before Tax	(299,200.00)	(129,560.00)	(74,968.00)	(873,490.00)
	(a) Current Tax	-	-	-	-
	(b) Deferred Tax	-	-	-	-
	(c) Tax expense relating to Earlier years	-	-	-	-
7	Profit for the Period	(299,200.00)	(129,560.00)	(74,968.00)	(873,490.00)
	Other Comprehensive Income				
	If any	-	-	-	-
	Total Comprehensive Income for the Period	(299,200.00)	(129,560.00)	(74,968.00)	(873,490.00)
14	Paid up Equity Share Capital (Face value Rs.10/- per-Equity Share)	197,381,000.00	197,381,000.00	197,381,000.00	197,381,000.00
16	Earning per share (before and after extraordinary items) (Rs.10- each)				
	Basic (Rs.)	(0.01)	(0.01)	(0.00)	(0.04)
	Diluted (Rs.)	(0.01)	(0.01)	(0.00)	(0.04)

Notes :

- The above Results, have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective Board
- The Statutory Auditors of the Company have carried out Limited Review of the above Results.
- Figures for the previous period have been re-classified, re-grouped/ re-arranged wherever necessary.
- There were no manufacturing activities in the company during the period under consideration
- The Company has adopted Indian Accounting Standards ("Ind AS") from April 1, 2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder.

PLACE: NEW DELHI

DATED: 14.08.2018

FOR AND ON BEHALF OF THE BOARD

NS Parameswaran
Managing Director
DIN: 00091097

Sangram Paul & Co.

Chartered Accountants

Plot No.754/15, Jayadev Vihar, Bhubaneswar-751 013
Phone: 0674-2360863 Mob.: 9337116878

S.K.Paul. F.C.A
Chartered Accountant

Review Report to MESCO PHARMACEUTICALS LIMITED

We have reviewed the accompanying statement of Unaudited financial results of **MESCO PHARMACEUTICALS LIMITED** for the quarter ended June 30, 2018, being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with SEBI circular CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with Indian Accounting Standard ("IND-AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles general accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No: CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sangram Paul & Co.
Chartered Accountants
Firm Registration No. 308001E


S.K. Paul
Proprietor
M. No.: - 013015



Date: 14th August, 2018
Place: New Delhi